Pharmaceuticals News and Research

RSS

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Sucampo Pharmaceuticals, Inc. and Abbott today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients.

10 May 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

KAEL-GemVax wins European telomerase patent challenge

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.

9 May 2011

caprotec bioanalytics closes Series B financing for EUR 5 million

caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry platform technology for the analysis of small molecule – protein interactions, today announced a second closing of EUR 1 million to its Series B financing, increasing total equity for the round to EUR 5 million.

9 May 2011

Flamel Technologies total revenues decrease to $6.8 million for first quarter 2011

Flamel Technologies today announced its financial results for the first quarter of 2011.

9 May 2011

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 in Asia and Europe, with the exception of Taiwan.

9 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 in Europe and Asia.

9 May 2011

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.

9 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Best Practices' report provides marketing, branding strategies for expanding multi-drug portfolio

In today's highly competitive marketplace, bio-pharmaceutical companies often look to expand their product portfolios in the same indication. This "double-dipping" can result in a new brand gaining more profitability at the expense of a more established brand.

9 May 2011

Cegedim Relationship Management's co-pay savings card programs presented at PMSA conference

The OPUS Health division of Cegedim Relationship Management conducted a presentation entitled Best Practices in ROI Methodologies in Analyzing the Effectiveness of Patient Co-pay Savings Cards at the 2011 Annual Pharmaceutical Management Science Association Conference in Miami, Florida.

7 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta extended-release 18, 27 and 36 mg tablets.

7 May 2011

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

sanofi-aventis and France’s Caisse des Dépôts announce today that the Caisse des Depots will acquire an interest in the Paris-based Biocitech life sciences technology park. Biocitech plays a key role in the development of the biotechnology industry in the department of Seine-Saint-Denis and the Greater Paris region.

7 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

West declares third quarter dividend of $0.17 per share

West Pharmaceutical Services, Inc. today announced that its Board of Directors has approved payment of the third-quarter 2011 cash dividend of $0.17 per share.

7 May 2011

Pharmaceuticals News and Research

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Novavax first quarter net loss decreases to $7.5 million

Unigene first quarter net loss decreases 58% to $6.6 million

KAEL-GemVax wins European telomerase patent challenge

caprotec bioanalytics closes Series B financing for EUR 5 million

Flamel Technologies total revenues decrease to $6.8 million for first quarter 2011

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Diamyd Medical announces European Phase III study results in type 1 diabetes

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Best Practices' report provides marketing, branding strategies for expanding multi-drug portfolio

Cegedim Relationship Management's co-pay savings card programs presented at PMSA conference

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Alza files patent infringement suit against Impax in connection with Concerta

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

West declares third quarter dividend of $0.17 per share

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence